Zymeworks Doses First Patient in Phase 1 Trial of ZW25, a Novel Bi-Specific Antibody for the Treatment of
HER2-Expressing Cancers
Zymeworks Inc., a biopharmaceutical company discovering and developing innovative multi-functional protein-based therapeutics,
including bi-specific antibodies and drug conjugates for the treatment of cancer, announced today that the first patient was dosed
in a Phase 1 clinical trial of ZW25 for treatment of HER2-expressing tumors.
As Zymeworks’ lead therapeutics program, ZW25 is a novel bi-specific antibody developed using the Company’s Azymetric™ platform.
The compound targets two different epitopes (bi-paratopic targeting) of the human epidermal growth factor receptor 2 (HER2)
protein, which is over-expressed on the surface of many tumor types, including certain breast, gastric, lung, and ovarian
cancers.
“We are excited to have begun enrollment in this initial study of ZW25,” said Diana Hausman, M.D., Zymeworks’ Chief Medical
Officer. “No approved HER2-targeted therapies exist for many patients with HER2-expressing cancers and with its unique mechanism of
action, ZW25 has the potential to address this significant unmet need.”
ZW25 is being evaluated in the clinic for safety, as well as efficacy, in patients with tumors with low to moderate levels of
HER2 expression. ZW25 is active in numerous in vivo models of HER2 low to high expressing cancers, including ovarian cancer,
for which it has received Orphan Drug Designation from the FDA. ZW25 has demonstrated an acceptable safety profile in preclinical
toxicology studies when administered at multiple dose levels using a once per week dosing schedule.
About ZW25
ZW25 is Zymeworks’ lead therapeutics program based on the Azymetric™ platform. It is an engineered bi-specific antibody that
targets two different epitopes (bi-paratopic targeting) of the HER2 protein and confers its efficacy via multiple mechanisms of
action, including: (i) enhanced antibody-mediated effector function resulting from the increased decoration of the tumor cell
surface; (ii) increased blockade of the HER2 cellular growth signal by the dual engagement of HER2 epitopes; and (iii) increased
removal of surface-expressed HER2 protein due to enhanced HER2 internalization upon antibody engagement. ZW25 is a best-in-class
HER2-targeting antibody for a variety of tumors characterized by HER2 overexpression, including breast, gastric, ovarian,
colorectal and non-small cell lung cancers. The FDA has granted Orphan Drug Designation to ZW25 for the treatment of ovarian
cancer.
About Zymeworks Inc.
Zymeworks is a privately held clinical-stage biotherapeutics company that is developing best-in-class Azymetric™ bi-specific
antibodies and antibody drug conjugates for the treatment of cancer, autoimmune and inflammatory diseases. The company’s novel
Azymetric™, AlbuCORE™, and EFECT™ platforms, its Zymelink™ conjugation platform and cytotoxins, and its proprietary ZymeCAD™
structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies, multivalent
protein therapeutics, and antibody drug conjugates across a range of indications. Zymeworks is focused on accelerating its
biotherapeutics pipeline through in-house research and development programs and strategic collaborations. More information on
Zymeworks can be found at www.zymeworks.com.
Media Inquiries
Michael Lampe, 484-575-5040
michael@scientpr.com
or
ICR Inc.
Investor Inquiries
Stephanie Carrington, 646-277-1282
stephanie.carrington@icrinc.com
or
Zymeworks Inc.
David Poon, Ph.D., 604-678-1388
Executive Director, External R&D and Alliances
bd@zymeworks.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160915005283/en/